Preclinical screening models are essential tools in pharmacological research that help evaluate the efficacy and safety of drugs before they are tested in humans. In particular, drugs acting on the autonomic nervous system (ANS) influence vital body functions such as heart rate, blood pressure, glandular secretion, muscle tone, and eye responses. This article presents a news-style educational overview of preclinical screening models used for assessing ANS activity, including sympathomimetics, sympatholytics, parasympathomimetics, parasympatholytics, skeletal muscle relaxants, drugs acting on the eye, and local anesthetics, with clear explanations suitable for educational websites.

Download UNIT 3 – Preclinical Screening Models for ANS Activity Notes

Get simplified revision notes for this unit:

⬇️

Download Unit 3 Notes PDF

Introduction to Preclinical Screening Models for ANS Activity

The autonomic nervous system regulates involuntary physiological functions and is divided into the sympathetic and parasympathetic systems. Drugs acting on the ANS can either stimulate or inhibit these pathways. Preclinical screening models are designed to study these effects in laboratory animals under controlled conditions.

These models help researchers understand the pharmacodynamic actions of drugs, identify therapeutic potential, and detect unwanted adverse effects. Proper selection of models ensures that the experimental outcomes are scientifically valid and clinically relevant.

Screening Models for Sympathomimetic Drugs

Evaluation of Sympathetic Stimulant Activity

Sympathomimetic drugs mimic the actions of the sympathetic nervous system. They are commonly used in conditions such as asthma, hypotension, and cardiac disorders.

In preclinical studies, these drugs are evaluated by observing physiological responses such as changes in heart rate, blood pressure, and bronchial tone.

Key parameters assessed include:

1. Increase in heart rate and cardiac output

2. Elevation of blood pressure

3. Bronchodilation and airway relaxation

4. Stimulation of smooth muscle responses

These models help determine the potency and selectivity of sympathomimetic agents.

Screening Models for Sympatholytic Drugs

Assessment of Sympathetic Blocking Effects

Sympatholytic drugs inhibit sympathetic activity and are commonly used as antihypertensive and antianginal agents. Preclinical screening focuses on the drug’s ability to reduce sympathetic responses.

Observed effects include:
• Reduction in blood pressure
• Decrease in heart rate
• Inhibition of vasoconstriction

Animal models allow researchers to compare the test drug with standard sympatholytic agents and evaluate dose-dependent effects.

Screening Models for Parasympathomimetic Drugs

Evaluation of Parasympathetic Stimulation

Parasympathomimetic drugs enhance parasympathetic activity and are used in conditions such as glaucoma, urinary retention, and gastrointestinal disorders. Screening models assess responses such as smooth muscle contraction and glandular secretion.

Common observations include:

1. Increased salivation and secretions

2. Contraction of smooth muscles

3. Reduction in heart rate

4. Changes in pupil size

These models help confirm cholinergic activity and therapeutic potential.

Screening Models for Parasympatholytic Drugs

Assessment of Parasympathetic Inhibition

Parasympatholytic drugs block parasympathetic activity and are widely used in ophthalmology, anesthesia, and gastrointestinal disorders.

Preclinical screening focuses on effects such as inhibition of secretions, relaxation of smooth muscles, and pupil dilation.

• Decreased salivary and bronchial secretions
• Increase in heart rate
• Mydriasis and cycloplegia

These responses help establish the anticholinergic profile of the drug.

Screening Models for Skeletal Muscle Relaxants

Evaluation of Neuromuscular Blocking Activity

Skeletal muscle relaxants act at the neuromuscular junction and are commonly used during surgical procedures. Preclinical screening models assess muscle tone, coordination, and reflex activity.

Key evaluation criteria include:

1. Reduction in muscle strength

2. Loss of righting reflex

3. Duration of muscle relaxation

4. Recovery time after drug withdrawal

Such models help differentiate centrally acting and peripherally acting muscle relaxants.

Screening Models for Drugs Acting on the Eye

Evaluation of Ocular Pharmacological Effects

Drugs acting on the eye are screened using models that assess pupil size, intraocular pressure, and ocular reflexes. These studies are essential for developing antiglaucoma agents and mydriatic drugs.

Common parameters studied include:
• Pupillary constriction or dilation
• Changes in intraocular pressure
• Duration of ocular effects

Animal models provide valuable insights into ocular drug safety and efficacy.

Screening Models for Local Anesthetics

Evaluation of Local Anesthetic Activity

Local anesthetics block nerve conduction and produce reversible loss of sensation. Preclinical screening models assess the onset, intensity, and duration of anesthesia.

Important assessment points include:

1. Time of onset of anesthesia

2. Degree of sensory blockade

3. Duration of anesthetic effect

4. Reversibility of nerve function

These models are crucial for comparing new local anesthetic agents with established standards.